Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings
HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | AIDS Research and Treatment |
| Online Access: | http://dx.doi.org/10.1155/2011/463704 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567016854126592 |
|---|---|
| author | Kevin Peterson Sabelle Jallow Sarah L. Rowland-Jones Thushan I. de Silva |
| author_facet | Kevin Peterson Sabelle Jallow Sarah L. Rowland-Jones Thushan I. de Silva |
| author_sort | Kevin Peterson |
| collection | DOAJ |
| description | HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no effect on HIV-2. Nucleoside analogues alone are not sufficiently potent enough to achieve durable virologic control. Some protease inhibitors, in particular those without ritonavir boosting, are not sufficiently effective against HIV-2. Following review of the available evidence and taking the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and highlight the needs of special populations. |
| format | Article |
| id | doaj-art-fb33051874af4a97aef03e5cbaa025f7 |
| institution | Kabale University |
| issn | 2090-1240 2090-1259 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | AIDS Research and Treatment |
| spelling | doaj-art-fb33051874af4a97aef03e5cbaa025f72025-02-03T01:02:34ZengWileyAIDS Research and Treatment2090-12402090-12592011-01-01201110.1155/2011/463704463704Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsKevin Peterson0Sabelle Jallow1Sarah L. Rowland-Jones2Thushan I. de Silva3Medical Research Council (UK) Laboratories, Atlantic Road, P.O. Box 273, Fajara, GambiaMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UKMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UKMedical Research Council (UK) Laboratories, Atlantic Road, P.O. Box 273, Fajara, GambiaHIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no effect on HIV-2. Nucleoside analogues alone are not sufficiently potent enough to achieve durable virologic control. Some protease inhibitors, in particular those without ritonavir boosting, are not sufficiently effective against HIV-2. Following review of the available evidence and taking the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and highlight the needs of special populations.http://dx.doi.org/10.1155/2011/463704 |
| spellingShingle | Kevin Peterson Sabelle Jallow Sarah L. Rowland-Jones Thushan I. de Silva Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings AIDS Research and Treatment |
| title | Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings |
| title_full | Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings |
| title_fullStr | Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings |
| title_full_unstemmed | Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings |
| title_short | Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings |
| title_sort | antiretroviral therapy for hiv 2 infection recommendations for management in low resource settings |
| url | http://dx.doi.org/10.1155/2011/463704 |
| work_keys_str_mv | AT kevinpeterson antiretroviraltherapyforhiv2infectionrecommendationsformanagementinlowresourcesettings AT sabellejallow antiretroviraltherapyforhiv2infectionrecommendationsformanagementinlowresourcesettings AT sarahlrowlandjones antiretroviraltherapyforhiv2infectionrecommendationsformanagementinlowresourcesettings AT thushanidesilva antiretroviraltherapyforhiv2infectionrecommendationsformanagementinlowresourcesettings |